Patent Grant
8071352
The present application is a National Phase Application of International Application No. PCT/KR2007/002995 filed Jun. 20, 2007, which claims priority to Korean Patent Application No. 10-2006-0055461 filed Jun. 20, 2006, which applications are incorporated herein fully by this reference.
The present invention relates to a novel bacteriophage having killing activity specific to Staphylococcus aureus.
A Bacteriophage is any one of a number of virus-like agents that infect bacteria and the term is commonly used in its shortened form, ‘phage’. Bacteriophages consist of an outer protein hull enclosing genetic material. The genetic material can be single stranded or double stranded DNA or RNA. To survive, bacteriophages need a host and every bacterium has a specific partner phage. When a bacteriophage invades into a host, it duplicates itself and then induces expressions of enzymes involved in the decomposition of cell wall of the host cell. The enzymes destroy cell wall by attacking murein or peptidoglycan which is responsible for rigidity and mechanical strength of the cell wall.
A bacteriophage was first found by Twort, an English bacteriologist, in 1915 during his research on the phenomenon that micrococcus colony is decomposed opaque by something. And in 1917, a French bacteriologist d′Herelle found out that there was something that decomposes Shigella disentriae in filtrate of feces of a patient with dysentery, and he continued to study to identify the material, leading to the finding of a bacteriophage which means “eating bacteria”. Since then, bacteriophages had been continuously identified specific to various pathogenic bacteria including Shigella, typhoid bacillus and comma bacillus. Dr. Delbruck of Cal-tech and some European scientists who had moved to USA during World War II focused their studies on the bacteriophage specific to E. coli. Since penicillin was discovered by Flemming in 1950, the antibiotic has been used widely and the research on bacteriophages has been limited to some Eastern European countries. However, multi-drug resistant pathogenic bacteria have been frequently reported since 2000, which must be resulted from the abuse and misuse of antibiotics. Based on its potential for alternative antibiotics, bacteriophages have been now in the center of the studies.
Even though antibiotics (or antibacterial agents) are still major therapeutic agents for the treatment of various infectious diseases, the antibiotics-based treatment has a serious problem. Numbers of multi-drug resistant strains have been found since 1980s, and it may be due to the excessive use of such antibiotics. In 1986, Staphylococcus aureus having resistance against vancomycin, which is so called ‘the last antibiotic’, and other multi-drug resistant strains were found, giving a great shock to those in medical field. Vancomycin resistant enterococci (VRE) was first reported in France in 1986 and first separated in USA in 1988. Since then, the cases of enterococci infection have been increased every year with high frequency, everywhere including Europe, USA, Singapore, Japan, Australia, Korea, etc, making the vancomycin resistant enterococci as a causal agent of nosocomial infections. In Korea, VRE was first isolated in 1992. Therefore, it is an urgent request to develop a novel antibiotic to treat the conventional antibiotic resistant bacteria and further to lead national health and medical techniques. To achieve the above goal, a novel antibiotic has to be developed through the completely different method. Again, it is urgently required to develop an alternative antibiotic to solve the problems of multi-drug resistant bacteria along with the abuse or misuse of the conventional antibiotics and the residual antibiotics.
Thus, the present inventors first isolated Staphylococcus aureus and subsequently isolated a bacteriophage that is able to kill selectively the previously isolated Staphylococcus aureus from the natural sources. Then, the inventors investigated the morphological, biochemical and genetic characteristics of the isolated bacteriophage to distinguish it from other bacterophages. The present inventors finally completed this invention by confirming that the Staphylococcus aureus specific bacteriophage isolated by the inventors can be effectively used for the prevention and treatment of the disease caused by Staphylococcus aureus.
It is an object of the present invention to provide a novel bacteriophage that is able to selectively kill Staphylococcus aureus, the causing agent of infectious diseases in human and animals.
It is another object of the present invention to provide a pharmaceutical composition for the prevention and treatment for the disease caused by Staphylococcus aureus containing the novel bacteriophage specific to Staphylococcus aureus as an active ingredient.
It is a further object of the present invention to provide an antibiotic containing the novel bacteriophage specific to Staphylococcus aureus as an active ingredient.
It is also an object of the present invention to provide a disinfectant containing the novel bacteriophage specific to Staphylococcus aureus as an active ingredient.
The present invention provides a novel bacteriophage belongs to T4-like phage genus, Myoviridae family, which has killing activity specific to Staphylococcus aureus, excellent acid resistance and thermo-stability, and the genome represented by the nucleotide sequence selected from the group consisting of sequences represented by SEQ. ID. NO: 1-NO: 26.
Staphylococcus aureus is a causing agent of skin infection and food poisoning. It is a very dangerous pathogenic bacterium having strong resistance against methicillin. It was reported that Staphylococcus aureus isolated in Korea has resistance against to methicillin as high as 73% at average, which is the top level in the world. That means 73% of Staphylococcus aureus cannot be killed by methicillin and this bacterium is highly antibiotic resistant.
The present inventors have endeavored to kill Staphylococcus aureus selectively. And at last, the inventors isolated Staphylococcus aureus from pathogen and further isolated a novel bacteriophage that is able to kill the isolated Staphylococcus aureus selectively. This novel bacteriophage having killing activity specific to Staphylococcus aureus, isolated by the inventors, was deposited at Korean Agricultural Culture Collection (KACC), National Institute of Agricultural Biotechnology (NIAB) on Jun. 14, 2006 (Accession No: KACC 97001 P) and deposited at the Korean Collection for Type Cultures (KCTC), located at the Korean Research Institute of Bioscience and Biotechnology (KRIBB), #52, Oun-dong, Yusong-ku, Taejon 305-333, Republic of Korea, on Jul. 10, 2007, and given the accession number KCTC 11153BP.
The bacteriophage of the present invention has such biochemical characteristics as acid resistance and thermo-stability. According to a preferred embodiment of the present invention, the bacteriophage of the invention can survive, in fact can be stable, at the temperature of 30-40° C. and also at low temperature of 4° C. (Example 2 and
The bacteriophage of the invention has not only killing activity specific to Staphylococcus aureus but also acid resistance and thermo-stability, so that it can be effectively used for the treatment of an animal or human with a disease caused by Staphylococcus aureus. The bacteriophage is not easily inactivated and maintains its killing activity stably in wide temperature and pH ranges.
The structural protein of the bacteriophage of the invention has the amino acid sequence selected from the group consisting of sequences represented by SEQ. ID. NO: 27-NO: 47.
According to a result of DNA sequencing with the genomic DNA of the bacteriophage of the invention, the bacteriophage has the nucleic acid molecule having the nucleotide sequence selected from the group consisting of sequences represented by SEQ. ID. NO: 1-NO: 26 (Example 3).
The term “nucleic acid molecule” herein includes DNA (gDNA and cDNA) and RNA, and the nucleotide, a constituent unit of the nucleic acid molecule, includes not only natural nucleotides but also analogues with modification of sugar or base (Scheit, Nucleotide Analogs, John Wiley, New York(1980); Uhlman and Peyman, Chemical Reviews, 90:543-584 (1990)).
The present invention also provides a pharmaceutical composition for the prevention and treatment of a disease caused by Staphylococcus aureus containing the aforementioned bacteriophage as an active ingredient.
The bacteriophage included in the pharmaceutical composition of the invention can kill Staphylococcus aureus specifically, so that it is very effective in treatment of various diseases caused by Staphylococcus aureus.
Staphylococcus aureus is the number one pathogenic bacterium to cause infectious mastitis in cattle. Staphylococcus aureus is found in 90% of the total dairy cows in USA and the dairy cow infected by this pathogenic bacterium in total dairy cows is estimated to be 10%. Staphylococcus aureus is a causing agent of acute dermatitis in human, and this acute dermatitis can be suddenly developed into sepsis taking a patient's life. Staphylococcus aureus is also a causing agent of pyogenic disease, sweat odor and food poisoning. Thus, the pharmaceutical composition of the present invention can be used for the treatment of various diseases caused by Staphylococcus aureus such as mastitis, acute dermatitis, sepsis, pyogenic disease, food poisoning, pneumonia, osteomyelitis, impetigo, bacteremia, endocarditis and enteritis. According to a preferred embodiment of the present invention, every day spray of the bacteriophage of the invention around a teat of dairy cow having mastitis could significantly reduce the symptoms of mastitis, suggesting that the bacteriophage of the invention is effective for the treatment of mastitis.
The term ‘treatment’ herein indicates (i) the prevention of the disease caused by Staphylococcus aureus; (ii) the suppression of the disease caused by Staphylococcus aureus; and (iii) the relief of the disease caused by Staphylococcus aureus.
The pharmaceutical composition of the present invention can additionally include a pharmaceutically acceptable carrier, which is exemplified by lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, but not always limited thereto. The pharmaceutical composition of the present invention can also include a lubricant, a wetting agent, a sweetener, a flavor, an emulsifier, a suspending agent, and a preservative, in addition to the above ingredients.
The pharmaceutical composition of the present invention can be applied or sprayed on the lesion, and administered orally or parenterally (for example, intravenous, intramuscular, hypodermic, local or peritoneal injection).
The effective dosage of the pharmaceutical composition of the present invention varies from the formulation, administration pathway, age, weight and gender of animal or human with a disease caused by Staphylococcus aureus, severity of a disease, diet, administration frequency and pathway, excretion and sensitivity. In general, the dosage can be determined by an experienced doctor with consideration of the goal of the treatment or preventive effect. According to an exemplary embodiment of the present invention, the pharmaceutical composition of the invention contains the bacteriophage at the concentration of 1×103−1×1010 pfu/μl.
The pharmaceutical composition of the present invention can be formulated as a unit dose medicine or as a medicine in multidose vehicle by mixing with a pharmaceutically acceptable carrier and/or excipient by the method well known to those in the art. The pharmaceutical formulation can be selected from a group consisting of ointments, solutions, suspensions or emulsions, extracts, powders, granules, tablets or capsules and additionally includes a dispersing agent or a stabilizing agent.
In another preferred embodiment of the present invention, the present invention provides an antibacterial agent for cosmetics and an antibiotic for medical use which contain the aforementioned bacteriophage as an active ingredient.
Staphylococcus aureus is frequently found in cosmetics along with Bacillus subtilis, E. coli and Pseudomonas aeruginosa. Cosmetics use oil or water as a major ingredient, to which glycerin and sorbitol, which are carbon sources of a microorganism, and amino acid derivatives and a protein which are nitrogen sources of a microorganism, are added, suggesting that there are enough nutrition and ingredients to attract microorganisms including bacteria. In addition, the term of use of the cosmetics is comparatively long, indicating that it is in high risk of contamination by a microorganism. To prevent color changes or odor changes caused by the contamination of a microorganism, an antibacterial agent is necessarily added to cosmetics for a long shelf-life.
A synthetic antiseptic such as parabens is widely used as an additive for cosmetics, but it is potentially dangerous. Particularly, since its accumulation in breast cancer cells was detected, it has been recognized that the accumulation of such synthetic antiseptic via cosmetics might be very harmful. The American Academy of Dermatology's Committee listed the synthetic antiseptic as the number two allergen causing skin trouble. Recently what worries us is that cosmetics for children also includes such artificial synthetic antiseptic, suggesting that children are exposed on such harmful antiseptic longer and much, raising the risk seriously. Therefore, it is sincerely requested to develop a natural antiseptic.
The bacteriophage of the present invention is characterized by its high specificity to Staphylococcus aureus, compared with other conventional antibiotics. That is, the bacteriophage can selectively kill Staphylococcus aureus only without killing useful bacteria, suggesting that it is a highly valuable antibiotic that has less side effects. The bacteriophage-based antibiotics, unlike the conventional antibiotics, do not induce resistance so that their life cyclings are comparatively long. Most conventional antibiotics are gradually limited in use because of the increasing resistance. On the other hand, the antibiotic containing the bacteriophage of the invention as an active ingredient can solve the problem of the antibiotic-resistance and thus has longer life cycling.
Therefore, the antibiotic containing the bacteriophage of the invention as an active ingredient that is able to kill Staphylococcus aureus selectively can be effectively used as a novel antibiotic with excellent antibacterial, bactericidal and antiseptic effects. The term ‘antibiotic’ is used herein as a general term for antiseptics, bactericidal agents and antibacterial agents.
In another preferred embodiment of the present invention, the invention provides a disinfectant containing the aforementioned bacteriophage as an active ingredient.
The distribution of bacteria isolated from nosocomial infection has been changed over time. According to a report of NNIS (National Nosocomial Infection Surveillance System), USA, Gram-positive bacteria particularly Staphylococcus aureus have been increasing in number among those isolated bacteria since late 1980s, and this phenomenon is consistent with that in Korea. According to a report made in Korea, the dominant distribution is E. coli, Pseudomonas aeruginosa, coagulase negative Staphylococcus and Staphylococcus aureus follows in that order. But, the isolation of Staphylococcus aureus is increasing gradually. Korean Society for Nosocomial Infection Control (KSNIC) reported in 1996 that Staphylococcus aureus took 17.2% of total isolated pathogenic microorganisms and Pseudomonas aeruginosa (13.8%) and E. coli (12.3%) followed. And, 78.8% of the total Staphylococcus aureus isolated were confirmed to have resistance against antibiotics.
Based on the above finding, the disinfectant containing the bacteriophage of the present invention that is able to kill specifically Staphylococcus aureus can be effectively used as a disinfectant specifically for hospitals and public health. It is also available as a general life disinfectant, a food and kitchen disinfectant, and a stall disinfectant.
The application of the preferred embodiments of the present invention is best understood with reference to the accompanying drawings, wherein:
Practical and presently preferred embodiments of the present invention are illustrative as shown in the following Examples.
However, it will be appreciated that those skilled in the art, on consideration of this disclosure, may make modifications and improvements within the spirit and scope of the present invention.
<1-1> Isolation of Staphylococcus aureus
Bacteriophages generally live together with bacteria in natural system. To isolate the bacteriophage specifically infecting Staphylococcus aureus, samples were collected from everywhere where the inventors expected Staphylococcus aureus lives. To investigate the samples where Staphylococcus aureus really exists, the Baird-Parker agar medium, a Staphylococcus aureus selection medium, was used.
Particularly, the present inventors selected dairy cow mastitis as a target disease to isolate Staphylococcus aureus, the target microorganism. Mastitis is one of the most representative diseases caused by Staphylococcus aureus. A sample was taken from milk of a dairy cow with mastitis and Staphylococcus aureus was isolated therefrom using the Baird-Parker agar medium, a Staphylococcus aureus selection medium. The isolated Staphylococcus aureus was identified as Staphylococcus aureus by biochemical analysis including Gram staining method, catalase test and analysis with Vitek of bioMeriuex. The results are shown in Table 1.
Staphylococcus aureus
<1-2> Isolation of the Staphylococcus aureus Specific Bacteriophage
To isolate a bacteriophage specific to the isolated Staphylococcus aureus, samples expected to contain the bacteriophage were cultured together with Staphylococcus aureus. The culture solution was centrifuged, filtered and then cultured again with Staphylococcus aureus, the bait for the isolation of a bacteriophage, and then lysis of Staphylococcus aureus was investigated. The lysis was finally verified by plaque assay.
Particularly, to isolate the bacteriophage having killing activity specific to Staphylococcus aureus, samples were collected from soil and straw in a cowshed and sewage where the bacteriophage was expected to be. These samples were cocultivated with the previously isolated Staphylococcus aureus at 37° C. for 3-4 hours. After cultivation, the culture broth was centrifuged for 20 minutes at 8,000 rpm. The supernatant was filtered with a 0.45 μm filter. With resultant filtrate, the Staphylococcus aureus specific bacteriophage was isolated by plaque assay. The method used for isolation of the Staphylococcus aureus specific bacteriophage is shown in the schematic diagram of
The obtained bacteriophage was tested for adsorption to its host, thermo-stability and acid resistance to define the biochemical characteristics. The basic media for the analysis were a TSB (tryptic soy broth) medium (casein digest, 17 g/l; soybean digest, 3 g/l; dextrose, 2.5 g/l; NaCl, 5 g/l; dipotassium phosphate, 2.5 g/l) which is a liquid medium for bacteria culture and a phage liquid medium (Bacto-peptone, 15 g/l; trypton, 8 g/l; bacto-yeast extract, 1 g/l; NaCl, 30 g/l; 1 mM MgSO4; 0.1 mM CaCl2; pH 7.2).
<2-1> Adsorption to Bacteria
To investigate bacteriophage adsorption to bacteria, 1 in of 108 cfu/ml Staphylococcus aureus solution was first mixed with 1 ml of 108 pfu/ml bacteriophage solution. The mixture was incubated at 37° C., during which 100 μl of the mixture was taken every 5 minutes. The obtained 100 μl of the mixture was 100 fold-diluted in the liquid medium for bacteria culture. Centrifugation was performed at 5,000 rpm for 10 minutes to precipitate Staphylococcus aureus only. After centrifugation, the 100 μl of supernatant containing the bacteriophage which was not adhered onto Staphylococcus aureus was recovered. From this, 5 μl was taken again. The number of bacteriophage non-adhered to Staphylococcus aureus in the 5 μl sample was counted to investigate when the bacteriophage was adhered to Staphylococcus aureus. As a result, bacteriophage was mostly adhered to the bacteria between 5 and 15 minutes from mixing (
<2-2> Thermo-Stability
To investigate the thermo-stability of the bacteriophage at different temperatures, 106 pfu/ml of bacteriophage solution was first prepared and then six 900 μl media were prepared. Six 900 μl media were incubated at different temperatures of 30, 37, 40, 50, 60 and 70° C. for minutes, to which 106 pfu/ml of the bacteriophage solution was added by 100 μl piper medium, followed by further incubation for 10 minutes. 100 μl was obtained therefrom and loaded on plate media by 5 μl per medium, followed by culture at 37° C. for overnight. After cultivation, the number of the bacteriophage survived was counted. At that time, the number of the bacteriophage survived at 37° C. was regarded as a standard. As a result, the bacteriophage was most stable at 30-40° C. and the survival rate decreased at the temperature higher than 40° C. (
Thermo-stability to cold shock (performed by adding a cold medium) was investigated. The temperature of a 4.5 ml medium was maintained at 60° C. and then 500 μl of 106 pfu/ml of bacteriophage solution was added thereto. 100 μl sample was taken every 10 minutes for one hour and then diluted in cold bacterial culture medium (4° C.). The number of bacteriophage in 5 μl diluted sample was counted by the same manner as described above and compared with the standard (the number of bacteriophage survived at 37° C.). As a result, the bacteriophage was stable to cold shock up to 10-20 minutes, but after then the bacteriophage became unstable (
<2-3> Acid Resistance
Acid resistance of the isolated bacteriophage was investigated by the similar manner as performed for the thermo-stability investigation. Survival rate of the bacteriophage was investigated in a medium in which pH was adjusted to 7.0, and the obtained value was considered as a standard. To test acid resistant, pH of each medium was respectively regulated to 3.0-10.0 (pH=3, 4, 5, 6, 7, 8, 9 and 10). 900 μl of sample solution was taken from each medium with different pH. 100 μl of 106 pfu/ml of bacteriophage solution was added thereto. The mixture was incubated at 37° C. for 10 minutes. After incubation, the number of the bacteriophage survived at each pH was counted by the same manner as described above. As a result, the bacteriophage was most stable at pH 5-8, and somewhat stable at pH 4, 9 and 10 but became unstable at pH 3 (
<2-4> Structural Protein of the Isolated Bacteriophage
To investigate the structural protein of the isolated bacteriophage, one-dimensional electrophoresis was performed. To obtain the protein composing the outer envelope of the bacteriophage, 250 μl of the bacteriophage solution was cultured. The bacteriophage was concentrated (250×) by using 1 in of 20% polyethylene glycol 8000/2.5 M NaCl aqueous solution. 200 μl of the concentrated bacteriophage sample and 800 μl of acetone were mixed vigorously and then the mixture was standing at −20° C. for 10 minutes. The mixture was centrifuged at 4° C., with 3,200 rpm for 20 minutes, followed by removal of supernatant and air drying of the resultant precipitate. The precipitate was resuspended in 50 μl of 5× electrophoresis sample buffer, followed by boiling for 5 minutes. The prepared sample was subjected to one-dimensional electrophoresis. As a result, as shown in
(1) Amino Acid Sequences of Around 50 kDa Protein
(2) Amino Acid Sequences of Around 60 kDa Protein
(3) Amino Acid Sequences of Around 90 kDa Protein
(4) Amino Acid Sequences of Around 120 kDa Protein
(5) Amino Acid Sequences of Around 150 kDa Protein
To identify the isolated bacteriophage, genotype and gene sequence of the genome extracted from it were analyzed. First, genome of the bacteriophage was extracted by the conventional method and the structural property of the genome was investigated.
Particularly, 200 ml of TSB medium, 50 ml of Staphylococcus aureus suspension (OD600=1) and 1 ml of filtered bacteriophage solution at the concentration of 108 pfu/ml were added into a 1l flask, followed by shaking-culture at 37° C. for 3-4 hours. Then, lysis of Staphylococcus aureus was observed. After confirming lysis, the culture solution was filtered with a 0.45 μm filter. After fitration, 20% polyethylene glycol 8000/2.5 M NaCl aqueous solution was added to the filtrate by the volume of ⅙ of the total volume of the filtrate, and the mixture was standing at 4° C. for overnight. Centrifugation was performed at 8,000 rpm for 20 minutes to obtain the bacteriophage pellet. The obtained bacteriophage precipitate was resuspended in 1 ml of phosphate buffer saline (PBS), to which 20% polyethylene glycol 8000/2.5 M NaCl aqueous solution was added again by the volume of ⅙ of the total volume of the resuspenssion solution. The mixture was standing at 4° C. again for one hour. One hour later, centrifugation was performed at 14,000 rpm for 10 minutes to obtain the purified bacteriophage precipitate. The precipitate was mixed with 200 μl of iodide buffer (10 mM Tris-HCl (pH 8.0), 1 mM EDTA, 4 M NaI). The mixture was standing at room temperature for 15 minutes, followed by extraction of the genome of the isolated bacteriophage by using DNeasy Tissue kit (Qiagen) and PCR purification kit (Labopass). To confirm whether the extracted genome of the bacteriophage was DNA or RNA, the genome was treated with DNase I (10 U/μl) and RNase A (10 μg/μl) at 37° C. for one hour, respectively. The genome was separatedly treated with mung bean nuclease (45 U/μl) for 15 minutes at room temperature to determine whether it was a single stranded DNA or a double-stranded DNA, in case it would be confirmed to be DNA. After enzymatic treatment, electrophoresis was performed with those prepared samples using 0.8% agarose gel and fragmentation pattern by each enzyme was investigated. As a result, the obtained genome was sensitive to DNase I and mung bean nuclease (
The genome extracted from the bacteriophage is a genomic DNA (gDNA). To analyze the gene sequence of the gDNA, the genome was treated with different restriction enzymes and fragmentation patterns by different restriction enzymes were observed. And the results are shown in
Particularly, partial digestion by a specific restriction enzyme (Msp I was used herein) is essential to obtain various gene fragments. According to the previous experiments, the treatment of the genome with MspI for one minute at 30° C. is appropriate for the construction of gDNA library. Thus, the fragments of gDNA of the bacteriophage were obtained by the foregoing partial digestion. The obtained fragments were introduced into pBluescript II SK(+) phagemid vector (Stratagene) using T4 ligase. The resultant recombinant plasmid having the fragment of the bacteriophage gene was introduced into E coli Top10F′ via electroporation, a kind of electro-transformation. The transformant with the recombinant plasmid was selected on the agar plate medium containing ampicillin supplemented with X-Gal (5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside) and isopropyl β-D-1-thiogalacto-pyranoside (IPTG) through Blue-White colony selection method. The selected single colony was inoculated into the liquid medium containing ampicillin, followed by shaking-culture for overnight. After cultivation, plasmids were extracted from the culture cells using a plasmid purification kit (iNtRON). The extracted plasmids were electrophoresed using 0.8% agarose gel to confirm the size. Based on the size, a recombinant plasmid was selected. The selection procedure is shown in
The nucleotide sequences obtained above were analyzed by using NCBI Blast program and the result is shown in
100 μl of the bacteriophage solution (108 pfu/ml) was added into 9 μl of nutrient broth (beef extract 3 g/t, peptone 5 g/l). A control medium was prepared without the addition of the bacteriophage solution. 100 μl of Staphylococcus aureus solution (108 cfu/ml) was added into each medium, followed by investigation of the growth of Staphylococcus aureus. In the medium not containing the bacteriophage solution, Staphylococcus aureus was growing so well. On the other hand, in the nutrition broth containing the bacteriophage solution, Staphylococcus aureus was not grown at all. It was confirmed from the above result that the bacteriophage isolated in example 1 was very effective in the prevention of the infection of Staphylococcus aureus.
10 dairy cows with mastitis caused by Staphylococcus aureus were selected to investigate the effect of the bacteriophage isolated in example 1 on mastitis. The cows were divided into two groups (5 cows per group). 10 in of bacteriophage solution (108 pfu/ml) was sprayed on one group every day and 10 ml of PBS without the bacteriophage was sprayed on the other group every day, particularly on the infected regions. The spray was continued for 10 days. As a result, significant treatment effect was observed in the group sprayed with the bacteriophage solution. From the result, it was confirmed that the bacteriophage isolated in example 1 was very effective in the treatment of the infectious disease caused by Staphylococcus aureus.
As explained hereinbefore, the present invention provides a novel bacteriophage that is able to kill specifically Staphylococcus aureus, a pathogenic microorganism. The bacteriophage of the invention can be effectively used in a variety of fields as a pharmaceutical composition for the prevention and treatment of infectious diseases caused by Staphylococcus aureus, as an antibacterial agent for cosmetics, as a natural antiseptic, and as a multi-purpose disinfectant.
Those skilled in the art will appreciate that the conceptions and specific embodiments disclosed in the foregoing description may be readily utilized as a basis for modifying or designing other embodiments for carrying out the same purposes of the present invention. Those skilled in the art will also appreciate that such equivalent embodiments do not depart from the spirit and scope of the invention as set forth in the appended claims.
[Receipt of a Deposit of Microorganism]
| Number | Date | Country | Kind |
|---|---|---|---|
| 10-2006-0055461 | Jun 2006 | KR | national |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/KR2007/002995 | 6/20/2007 | WO | 00 | 5/27/2009 |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2007/148919 | 12/27/2007 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 6056954 | Fischetti | May 2000 | A |
| 6056955 | Fischetti | May 2000 | A |
| 6121036 | Ghanbari | Sep 2000 | A |
| 6264945 | Fischetti | Jul 2001 | B1 |
| 6432444 | Fischetti et al. | Aug 2002 | B1 |
| 7572602 | Donovan | Aug 2009 | B1 |
| 7582291 | Yoong | Sep 2009 | B2 |
| 20030152594 | Pillich | Aug 2003 | A1 |
| 20030216338 | Merril | Nov 2003 | A1 |
| 20040091470 | Fischetti et al. | May 2004 | A1 |
| 20040146490 | Kelly | Jul 2004 | A1 |
| 20050260171 | Ghanbari et al. | Nov 2005 | A1 |
| 20070025978 | Yoong | Feb 2007 | A1 |
| 20070077235 | Loomis | Apr 2007 | A1 |
| 20100004321 | Ross | Jan 2010 | A1 |
| 20100144619 | Yoon et al. | Jun 2010 | A1 |
| 20100203019 | Yoon et al. | Aug 2010 | A1 |
| 20100203180 | Yoon et al. | Aug 2010 | A1 |
| 20100254950 | Yoon et al. | Oct 2010 | A1 |
| Number | Date | Country |
|---|---|---|
| 2006-55461 | Jun 2006 | KR |
| 2006-73562 | Aug 2006 | KR |
| 2007-82358 | Aug 2007 | KR |
| 1007-81669 | Dec 2007 | KR |
| WO 03067991 | Aug 2003 | WO |
| WO 2004020451 | Mar 2004 | WO |
| WO 2004062677 | Jul 2004 | WO |
| WO 2006063176 | Jun 2006 | WO |
| WO 2007148919 | Dec 2007 | WO |
| WO 2008016240 | Feb 2008 | WO |
| WO 2009035303 | Mar 2009 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 20100267117 A1 | Oct 2010 | US |
